OncoMatch/Clinical Trials/NCT05630209
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
Is NCT05630209 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Exablate and Doxorubicin for brain tumor.
Treatment: Exablate · Doxorubicin — The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: radiation therapy
At least 4-week and not greater than 12 weeks from completion of radiation therapy
Cannot have received: chemotherapy
Previous participation in other chemotherapy, molecularly targeted therapy, or immunotherapy treatment-related phase 1 or 2 trials
Cannot have received: molecularly targeted therapy
Previous participation in other chemotherapy, molecularly targeted therapy, or immunotherapy treatment-related phase 1 or 2 trials
Cannot have received: immunotherapy
Previous participation in other chemotherapy, molecularly targeted therapy, or immunotherapy treatment-related phase 1 or 2 trials
Cannot have received: anthracycline (doxorubicin, daunorubicin, idarubicin)
Previous treatment with complete cumulative doses of Doxorubicin, daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones
Cannot have received: anthracenedione
Previous treatment with complete cumulative doses of Doxorubicin, daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones
Lab requirements
Kidney function
Severely impaired renal function with estimated glomerular filtration rate <2 standard deviations for age [excluded]
Severely impaired renal function with estimated glomerular filtration rate <2 standard deviations for age
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's National Medical Center · Washington D.C., District of Columbia
- Nicklaus Children's Hospital · Miami, Florida
- Cook Children's Health Care System · Fort Worth, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify